Detalles del proyecto
Descripción
The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society.
The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are:
• INFRAFRONTIER Business Plan2.0 and business models for all services
• Stable legal framework built on the INFRAFRONTIER legal entity
• INFRAFRONTIER annual stakeholder conferences
• Customised mouse model and secondary phenotyping pilot services
• INFRAFRONTIER advanced training schools in mouse phenogenomics
• Reengineered EMMA Database2.0 system
• Annotated mouse models of human diseases
• Quality management system for the legal entity
INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium
The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are:
• INFRAFRONTIER Business Plan2.0 and business models for all services
• Stable legal framework built on the INFRAFRONTIER legal entity
• INFRAFRONTIER annual stakeholder conferences
• Customised mouse model and secondary phenotyping pilot services
• INFRAFRONTIER advanced training schools in mouse phenogenomics
• Reengineered EMMA Database2.0 system
• Annotated mouse models of human diseases
• Quality management system for the legal entity
INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium
| Sigla | INFRAFRONTIER |
|---|---|
| Estado | Finalizado |
| Fecha de inicio/Fecha fin | 1/01/17 → 31/12/21 |
Socios colaboradores
- Centre Européen pour la Recherche en Biologie et Médecine - Groupement d'Intérêt Economique (Socio del proyecto)
- Consiglio Nazionale delle Ricerche (CNR) (Socio del proyecto)
- Centre National de la Recherche Scientifique (CNRS) (Socio del proyecto)
- Consejo Superior de Investigaciones Científicas (CSIC) (Socio del proyecto)
- European Molecular Biology Laboratory (EMBL) (Socio del proyecto)
- Biomedical Sciences Research Center "Alexander Fleming" (BSRC Al. Fleming) (Socio del proyecto)
- Fundaçao Calouste Gulbenkian (Socio del proyecto)
- USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE (Socio del proyecto)
- Genome Research Ltd. (Socio del proyecto)
- Helmholtz-Zentrum fuer Infektionsforschung GmbH (Socio del proyecto)
- Institut National de la Santé et de la Recherche Médicale (INSERM) (Socio del proyecto)
- Institut Pasteur (Socio del proyecto)
- Karolinska Institutet (KI) (Socio del proyecto)
- Medizinische Hochschule Hannover (MHH) (Socio del proyecto)
- Medical Research Council (MRC) (Socio del proyecto)
- Stichtint het nederlands Kanker Institut (Socio del proyecto)
- Toronto Center for Phenogenomics Inc. (Socio del proyecto)
- Tel Aviv University (Socio del proyecto)
- TSE SYSTEMS GMBH (Socio del proyecto)
- University of Oulu (Socio del proyecto)
- University of Sheffield (Socio del proyecto)
- Veterinaermedizinische Universitaet Wien (Socio del proyecto)
- Ayoxxa biosystems (Socio del proyecto)
- BIOMEDCODE S.A. (Socio del proyecto)
- Infrafrontier GmbH (Socio del proyecto)
- University of Copenhagen (Socio del proyecto)
- Academisch ziekenhuis groningen (Socio del proyecto)
- Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (Socio del proyecto)
Financiación
- Comisión Europea (CE): 4.955.880,00 €

Huella digital
Explore los temas de investigación que se abordan en este proyecto. Estas etiquetas se generan con base en las adjudicaciones/concesiones subyacentes. Juntos, forma una huella digital única.